Fig. 1 Bis In^{3+} IMP 274



Fig. 2 Bis In^{3+} IMP 274 (SN-38 analog)



Fig. 3 Bis In^{3+} IMP 274 (SN-38 analog with penicillamine linker)



Fig. 4 Bis In^{3+} IMP 274 (SN-38 analog linked to a cysteine using a hindered ester)



Fig. 5 IMP 225



Fig. 6 Bis In^{3+} IMP 224



Fig. 7 HPLC analysis (Reverse Phase) of ^{111}In-Labeled IMP 274



Fig. 8 HPLC Analysis (Size Exclusion) of ^{111}In-Labeled IMP 274



Fig. 9A HPLC analysis (Reverse Phase) of ^{111}In-Labeled IMP 274 in Mouse Serum



Fig. 9B HPLC analysis (Reverse Phase) of ^{111}In-Labeled IMP 274 in Mouse Serum



Fig. 10A HPLC analysis (Reverse Phase) of ^{111}In-Labeled IMP 274 in Human Serum



Fig. 10B HPLC analysis (Reverse Phase) of ^{111}In-Labeled IMP 274 in Human Serum



Fig. 11 HPLC analysis (Size Exclusion) of ^{111}In-Labeled IMP 274 in Mouse Serum containing bsAb 734xhMN14



Fig. 12 HPLC analysis (Size Exclusion) of ^{111}In-Labeled IMP 274 in Human Serum containing bsAb 734xhMN14



Fig. 13 Stability of IMP 294 (A) and IMP 295 (B) in PBS at 25°C Over 7 Days

A



B



Fig. 14 Pre-targeting in SCID Mice

A.

SCID Mice Inoculated i.v. with 1.5 x 10^7 Daudi Cells					
Group	**(N)**	**Treatment**	**Ratio**	**Dose**	**Schedule**
I	9	LL2x734 IMP-225	(1:1)	300 µg (3 x 10^{-9} moles) ~6 µg (3 x 10^{-9} moles)	Days 1, 3, 7, 9 Days 2, 4, 8, 10
II	8	IMP-225 Alone	N/A	~30 µg (1.5 x 10^{-8} moles)	Days 2, 4, 8, 10

B.



Fig. 15 Synthesis of DTPA Precursor and DTPA (Three Step Method)



Fig. 16 Synthesis of DTPA Precursor and DTPA (Four Step Method)